MCID: BRS049
MIFTS: 44

Breast Carcinoma in Situ malady

Cancer category

Summaries for Breast Carcinoma in Situ

Sources:
33MalaCards
See all sources

Fully expand this MalaCard

Export this MalaCard
MalaCards: Breast Carcinoma in Situ, also known as non-infiltrating carcinoma of breast, is related to breast apocrine carcinoma and poland syndrome. An important gene associated with Breast Carcinoma in Situ is LIF (leukemia inhibitory factor), and among its related pathways are CREB Pathway and Malaria. The compounds cycloheximide and tamoxifen have been mentioned in the context of this disorder. Related mouse phenotypes are limbs/digits/tail and adipose tissue.

Aliases & Classifications for Breast Carcinoma in Situ

Sources:
8Disease Ontology, 57SNOMED-CT, 61UMLS, 40NCIt, 27ICD9CM, 25ICD10
See all sources

Classifications:

Malacards categories (disease lists): (See all malacards categories)
Global: Cancer


Aliases & Descriptions:

breast carcinoma in situ 8
non-infiltrating carcinoma of breast 8
carcinoma in situ of breast 8


External Ids:

Disease Ontology8 DOID:8791
NCIt40 C3641
ICD9CM27 233.0
ICD1025 D05

Related Diseases for Breast Carcinoma in Situ

Sources:
17GeneCards, 18GeneDecks
See all sources

Diseases related to Breast Carcinoma in Situ via text searches within MalaCards or GeneCards/GeneDecks gene sharing:

(show top 50)    (show all 153)
idRelated DiseaseScoreTop Affiliating Genes
1breast apocrine carcinoma10.2
2poland syndrome10.2
3female breast carcinoma10.2
4mondor disease10.2
5hypoxia10.2
6breast cancer, lobular10.2
7pituitary adenoma10.0LIF
8malaria10.0LIF
9angiosarcoma10.0VEGFC
10dermatitis10.0LIF
11cervical intraepithelial neoplasia10.0VEGFC
12ischemia10.0VEGFC
13von hippel-lindau disease10.0MET
14chordoma10.0KRT19
15dilated cardiomyopathy10.0IL6ST
16nephritis10.0LIF
17breast-ovarian cancer, familial, 210.0BRCA2
18acute leukemia10.0IL6ST
19multiple endocrine neoplasia10.0BRCA2
20colon adenocarcinoma10.0CDH1
21gallbladder cancer10.0TP53
22neuroblastoma10.0TP53
23gastritis10.0TP53
24infertility10.0IL6ST, LIF
25teratoma10.0LIF
26skin cancer10.0TP53
27prolactinoma10.0IL6ST, LIF
28proliferative diabetic retinopathy10.0MET
29ulcerative colitis10.0TP53
30pheochromocytoma10.0LIF, IL6ST
31uterine carcinosarcoma10.0ERBB2
32hepatoblastoma10.0LIF, MET
33leiomyosarcoma10.0TP53
34pemphigus vulgaris10.0CDH1
35werner syndrome10.0BRCA1
36gastrointestinal system disease10.0CDH1
37papilloma10.0TP53
38wilms tumor10.0VEGFC, BRCA2
39chondrosarcoma10.0KRT19, MET
40hereditary diffuse gastric cancer10.0CDH1
41cystadenoma10.0BRCA1, VEGFC
42malignant mesothelioma10.0CDH1, MET
43bilateral breast cancer10.0BRCA1, BRCA2
44neutropenia10.0ERBB2, LIF
45aplastic anemia10.0BRCA2, BRCA1
46laryngeal carcinoma10.0TP53, VEGFC
47liver cirrhosis10.0TGFB1
48biliary tract cancer10.0MET, ERBB2
49brca1 and brca2 hereditary breast and ovarian cancer10.0BRCA1, BRCA2
50fanconi's anemia10.0BRCA2, BRCA1

Graphical network of the top 20 diseases related to Breast Carcinoma in Situ:



Diseases related to breast carcinoma in situ

Clinical Features for Breast Carcinoma in Situ

Drugs & Therapeutics for Breast Carcinoma in Situ

Sources:
5CenterWatch, 42NIH Clinical Center, 6ClinicalTrials
See all sources

Approved drugs:

Search CenterWatch for Breast Carcinoma in Situ

Drug clinical trials:

Search ClinicalTrials for Breast Carcinoma in Situ

Search NIH Clinical Center for Breast Carcinoma in Situ

Search CenterWatch for Breast Carcinoma in Situ

Genetic Tests for Breast Carcinoma in Situ

Anatomical Context for Breast Carcinoma in Situ

Animal Models for Breast Carcinoma in Situ or affiliated genes

Sources:
37MGI, 28inGenious Targeting Laboratory
See all sources

MGI Mouse Phenotypes related to Breast Carcinoma in Situ:

37 (show all 23)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:000537110.2BRCA2
2MP:000537510.1LIF
3MP:00053919.9LIF
4MP:00053809.6KRT19, ERBB2
5MP:00053699.5TP53, TGFB1, MET
6MP:00053769.4IL6ST, BRCA1, BRCA2, LIF
7MP:00036318.4IL6ST, LIF, ERBB2, TGFB1, KRT19
8MP:00053888.2TP53, TGFB1, ERBB2, IL6, BRCA1, LIF
9MP:00053708.2LIF, IL6, IL6ST, TP53, TGFB1, MET
10MP:00053908.1IL6ST, IL6, LIF, BRCA2, BRCA1, KRT19
11MP:00053977.9BRCA1, BRCA2, LIF, IL6, IL6ST, TP53
12MP:00020067.8KRT19, TGFB1, ERBB2, SDC1, MET, CDH1
13MP:00053897.6TGFB1, BRCA2, BRCA1, LIF, CDH1, KRT19
14MP:00053797.4BRCA2, BRCA1, IL6, IL6ST, KRT19, TP53
15MP:00028737.4CDH1, BRCA1, BRCA2, MET, TP53, ERBB2
16MP:00053867.4IL6, OSM, LIF, ERBB2, TP53, BRCA2
17MP:00053876.8CDH1, TGFB1, SDC1, TP53, IL6ST, IL6
18MP:00053856.5CDH1, KRT19, ERBB2, TP53, IL6ST, IL6
19MP:00053816.5TP53, ERBB2, TGFB1, BRCA1, BRCA2, MET
20MP:00107716.5OSM, BRCA1, TP53, BRCA2, KRT19, IL6
21MP:00053786.4BRCA1, TP53, ERBB2, LIF, IL6ST, MET
22MP:00053845.9KRT19, BRCA1, BRCA2, MET, CDH1, LIF
23MP:00107685.7BRCA1, BRCA2, MET, LIF, TGFB1, IL6

Publications for Breast Carcinoma in Situ

Sources:
51PubMed
See all sources

Articles related to Breast Carcinoma in Situ:

(show top 50)    (show all 214)
idTitleAuthorsYear
1
Time trends and inter-hospital variation in treatment and axillary staging of patients with ductal carcinoma in situ of the breast in the era of screening in Southern Netherlands. (24291376)
2014
2
Synchronous ductal carcinoma in situ of the breast and within epithelial inclusions in an ipsilateral sentinel lymph node. (23089490)
2013
3
Combined inhibition of ErbB1/2 and Notch receptors effectively targets breast ductal carcinoma in situ (DCIS) stem/progenitor cell activity regardless of ErbB2 status. (23457626)
2013
4
Role of HGF in epithelial-stromal cell interactions during progression from benign breast disease to ductal carcinoma in situ. (24025166)
2013
5
EZH2 and ALDH1 expression in ductal carcinoma in situ: complex association with recurrence and progression to invasive breast cancer. (23759596)
2013
6
Extensive pure ductal carcinoma in situ of the breast: Identification of predictors of associated infiltrating carcinoma and lymph node metastasis before immediate reconstructive surgery. (24388733)
2013
7
Paired ductal carcinoma in situ and invasive breast cancer lesions in the D-loop of the mitochondrial genome indicate a cancerization field effect. (23509716)
2013
8
Quality indicators for ductal carcinoma in situ (DCIS) of the breast: development using a multidisciplinary delphi process and its use in monitoring population-based treatment. (24038038)
2013
9
Neuroendocrine ductal carcinoma in situ, comedo type, of the breast detected by screening mammography: a potentially pre-invasive counterpart of high grade neuroendocrine tumours. (22437750)
2012
10
Combined evaluation of CK5/6, ER, p63, and MUC3 for distinguishing breast intraductal papilloma from ductal carcinoma in situ. (22612506)
2012
11
The role of breast MR imaging in pre-operative determination of invasive disease for ductal carcinoma in situ diagnosed by needle biopsy. (22205445)
2012
12
Differentially expressed genes regulating the progression of ductal carcinoma in situ to invasive breast cancer. (22751464)
2012
13
Conservative treatment of breast ductal carcinoma in situ: results of an Italian multi-institutional retrospective study. (23098066)
2012
14
Ductal carcinoma in situ that involves sclerosing adenosis: high frequency of bilateral breast cancer occurrence. (23083502)
2012
15
Asymptomatic Incidental Ductal Carcinoma in situ in a Male Breast Presenting with Contralateral Gynecomastia. (22530182)
2012
16
Serum autoantibody signature of ductal carcinoma in situ progression to invasive breast cancer. (22322670)
2012
17
Incidence and possible pathogenesis of sentinel node micrometastases in ductal carcinoma in situ of the breast detected using molecular whole lymph node assay. (22531630)
2012
18
Intraoperative assessment of surgical margins during breast conserving surgery of ductal carcinoma in situ by use of radiofrequency spectroscopy. (21885281)
2011
19
Is CD56 a specific and reliable neuroendocrine marker for discriminating between endocrine/neuroendocrine ductal carcinoma in situ and intraductal papilloma of the breast? (21166944)
2011
20
Increased breast density correlates with the proliferation-seeking radiotracer (99m)Tc(V)-DMSA uptake in florid epithelial hyperplasia and in mixed ductal carcinoma in situ with invasive ductal carcinoma but not in pure invasive ductal carcinoma or in mild epithelial hyperplasia. (21521552)
2011
21
Ductal carcinoma in situ of the breast: influence of age on diagnostic, therapeutic, and prognostic features. Retrospective study of 812 patients. (21108045)
2011
22
Indication for sentinel lymph node biopsy for breast cancer when core biopsy shows ductal carcinoma in situ. (21741518)
2011
23
Different distribution of breast cancer subtypes in breast ductal carcinoma in situ (DCIS), DCIS with microinvasion, and DCIS with invasion component. (21042943)
2011
24
Inclusion of tumor biology molecular markers to improve the ductal carcinoma in situ ipsilateral breast tumor recurrence nomogram predictability. (21172894)
2011
25
Molecular diversity in ductal carcinoma in situ (DCIS) and early invasive breast cancer. (20663721)
2010
26
Molecular differences between ductal carcinoma in situ and adjacent invasive breast carcinoma: a multiplex ligation-dependent probe amplification study. (20978320)
2010
27
Estrogen receptor, progesterone receptor, and glucocorticoid receptor expression in normal breast tissue, breast in situ carcinoma, and invasive breast cancer. (19875955)
2010
28
Costimulatory molecule OX40/OX40L expression in ductal carcinoma in situ and invasive ductal carcinoma of breast: an immunohistochemistry-based pilot study. (20634005)
2010
29
Pregnancy-related factors and the risk of breast carcinoma in situ and invasive breast cancer among postmenopausal women in the California Teachers Study cohort. (20565829)
2010
30
Intracrinology of sex steroids in ductal carcinoma in situ (DCIS) of human breast: comparison to invasive ductal carcinoma (IDC) and non-neoplastic breast. (19444935)
2009
31
D2-40 expression by breast myoepithelium: potential pitfalls in distinguishing intralymphatic carcinoma from in situ carcinoma. (18206495)
2008
32
Intratumoral concentration of sex steroids and expression of sex steroid-producing enzymes in ductal carcinoma in situ of human breast. (18310280)
2008
33
OSM, LIF, its receptors, and its relationship with the malignance in human breast carcinoma (in situ and in infiltrative). (18317962)
2008
34
P63 and cytokeratin8/18 expression in breast, atypical ductal hyperplasia, ductal carcinoma in situ and invasive duct carcinoma. (19190693)
2007
35
Expression of cytokeratin markers, ER-alpha, PR, HER-2/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast. (17522367)
2007
36
Expression of androgen receptor and two androgen-induced proteins (apolipoprotein D and pepsinogen C) in ductal carcinoma in situ of the breast. (17543076)
2007
37
Synchronous bilateral ductal carcinoma in situ of the male breast associated with gynecomastia in a 30-year-old patient following repeated injections of stanozolol. (16328719)
2006
38
Expression of sialyl lewis X, sialyl Lewis A, E-cadherin and cathepsin-D in human breast cancer: immunohistochemical analysis in mammary carcinoma in situ, invasive carcinomas and their lymph node metastasis. (16033070)
2005
39
Loss of heterozygosity at BRCA2 in a ductal carcinoma in situ and three invasive breast carcinomas in a family with a germline BRCA2 mutation. (15528970)
2004
40
Loss of aurora A/STK15/BTAK overexpression correlates with transition of in situ to invasive ductal carcinoma of the breast. (14693746)
2003
41
Invasive ductal carcinoma of the breast: study of the number of copies of the CCND1 gene and chromosome 11 using fluorescence in situ hybridization (FISH) in comparison with expression of cyclin D1 protein and estrogen receptors (ER alpha) with immunohistochemical detection]. (12532908)
2002
42
Incidence of second cancers among women with in situ carcinoma of the breast. (14965621)
2001
43
Collagenase-3 expression in breast myofibroblasts as a molecular marker of transition of ductal carcinoma in situ lesions to invasive ductal carcinomas. (11585740)
2001
44
Down-regulation of gelsolin expression in human breast ductal carcinoma in situ with and without invasion. (10481945)
1999
45
Genetic alterations in early-onset invasive breast carcinomas: correlation of c-erbB-2 amplification detected by fluorescence in situ hybridization with p53 accumulation and tumor phenotype. (10502729)
1999
46
Simultaneous loss of E-cadherin and catenins in invasive lobular breast cancer and lobular carcinoma in situ. (9496256)
1997
47
Fluorescence in situ hybridization assessment of chromosome 8 copy number in stage I and stage II infiltrating ductal carcinoma of the breast. (9283590)
1997
48
Prognostic significance of in situ carcinoma associated with invasive breast carcinoma: a natural experiment in cancer immunology? (9129007)
1997
49
Quantitative study of ductal breast cancer progression. A progression index (P.I.) for premalignant lesions and in situ carcinoma. (8832747)
1996
50
Transforming growth factor beta 1 in ductal carcinoma in situ and invasive carcinomas of the breast. (1317202)
1992

Genetic Variations for Breast Carcinoma in Situ

Expression for genes affiliated with Breast Carcinoma in Situ

Sources:
1BioGPS, 15Gene Expression Omnibus DataSets
See all sources
Expression patterns in normal tissues for genes affiliated with Breast Carcinoma in Situ

Search GEO for disease gene expression data for Breast Carcinoma in Situ.

Pathways for genes affiliated with Breast Carcinoma in Situ

Sources:
52QIAGEN, 30KEGG, 12EMD Millipore, 60Tocris Bioscience, 54Reactome, 38NCBI BioSystems Database, 53R&D Systems, 56SinoBiological
See all sources

Pathways related to Breast Carcinoma in Situ according to GeneCards/GeneDecks:

(show top 50)    (show all 55)
idSuper pathways (with members indented)ScoreTop Affiliating Genes
1
Hide members
10.2VEGFC
210.0SDC1
310.0SDC1
4
Hide members
10.0MET, VEGFC
5
Hide members
9.8IL6, MET
69.7TP53, BRCA1
79.7IL6, TGFB1
8
Hide members
9.7TP53, ERBB2
9
Hide members
9.6MET, VEGFC, ERBB2
10
Hide members
9.6TGFB1, SDC1
11
Hide members
9.6TGFB1, SDC1
129.6IL6, VEGFC, LIF
13
Hide members
9.6VEGFC, CDH1, ERBB2
149.5ERBB2, CDH1, MET
15
DNA damage Role of Brca1 and Brca2 in DNA repair
Hide members
9.4TP53, BRCA2, BRCA1
169.4BRCA1, BRCA2, TP53
17
Hide members
9.4BRCA1, BRCA2, TP53
189.4TP53, ERBB2, MET
199.4CDH1, ERBB2, TP53
209.3LIF, IL6ST, TGFB1
219.3TGFB1, SDC1, MET
229.2TGFB1, TP53, IL6
239.2IL6, IL6ST, ERBB2
24
Hide members
9.2MET, VEGFC, IL6, TGFB1
259.2IL6, IL6ST, TGFB1
26
Cytokine production by Th17 cells in CF (Mouse model)
9.2TGFB1, IL6ST, IL6
27
Hide members
9.2TGFB1, IL6ST, IL6
289.2BRCA1, VEGFC, CDH1, TP53
299.1BRCA1, MET, ERBB2, TP53
309.1TP53, CDH1, BRCA2, BRCA1
319.1OSM, LIF, IL6ST
32
Hide members
9.1TP53, ERBB2, CDH1, MET
33
Hide members
9.0BRCA2, ERBB2, TP53, TGFB1
34
Translation Insulin regulation of translation
Hide members
9.0MET, IL6ST, ERBB2, TGFB1
35
Hide members
9.0LIF, IL6, IL6ST, ERBB2
36
Immune response Oncostatin M signaling via JAK-Stat in human cells
Hide members
8.9OSM, IL6, IL6ST
37
G-protein signaling Ras family GTPases in kinase cascades (scheme)
Hide members
8.9TP53, IL6ST, OSM
38
Transcription Androgen Receptor nuclear signaling
Hide members
8.8IL6, IL6ST, ERBB2, TGFB1
398.7TGFB1, TP53, ERBB2, BRCA2, BRCA1
408.7TGFB1, TP53, IL6ST, IL6
418.5MET, ERBB2, TP53, SDC1, TGFB1
42
Hide members
8.4TGFB1, ERBB2, VEGFC, LIF, MET, OSM
438.3TGFB1, IL6ST, IL6, LIF, OSM
448.3TGFB1, BRCA2, CDH1, IL6, ERBB2, TP53
458.2BRCA1, OSM, MET, VEGFC, IL6, TP53
46
Hide members
8.1BRCA1, BRCA2, VEGFC, IL6, ERBB2, TP53
47
Hide members
7.6MET, LIF, VEGFC, IL6, IL6ST, ERBB2
48
Hide members
7.5OSM, MET, LIF, VEGFC, IL6, ERBB2
49
Hide members
7.4OSM, MET, LIF, VEGFC, IL6, IL6ST
50
Hide members
6.9BRCA1, OSM, MET, LIF, VEGFC, CDH1

Compounds for genes affiliated with Breast Carcinoma in Situ

Sources:
45Novoseek, 50PharmGKB, 29IUPHAR, 11DrugBank, 24HMDB, 60Tocris Bioscience, 2BitterDB
See all sources

Compounds related to Breast Carcinoma in Situ according to GeneCards/GeneDecks:

(show top 50)    (show all 120)
idCompoundScoreTop Affiliating Genes
1cycloheximide4510.3BRCA1, BRCA2
2tamoxifen45 50 29 1112.8TGFB1, ERBB2, CDH1
3pge2459.7CDH1, TGFB1, MET, VEGFC
4estradiol45 11 2411.6VEGFC, OSM, BRCA2
5il 11459.5IL6, LIF, OSM
6indole-3-carbinol459.5BRCA2, CDH1, BRCA1, TP53
7methylcellulose459.4IL6, LIF, TGFB1, CDH1
8heparin45 29 11 2412.3ERBB2, CDH1, LIF, BRCA1
94-hydroxytamoxifen459.3TGFB1, BRCA2, ERBB2, BRCA1
10vitamin d459.3IL6ST, IL6, ERBB2, MET
11depsipeptide459.1TP53, OSM, CDH1, LIF
12bleomycin45 1110.1BRCA1, BRCA2, TP53, TGFB1
13bortezomib45 1110.0BRCA1, TP53, ERBB2, IL6
145fluorouracil459.0TP53, ERBB2, CDH1, BRCA1, LIF
15matrigel459.0LIF, BRCA2, CDH1, KRT19, MET
16ifn-alpha458.9IL6, LIF, OSM, IL6ST
17pdtc458.9MET, TGFB1, TP53, IL6
18carboplatin45 50 1110.9TP53, ERBB2, LIF, BRCA1
19tgf beta1458.8OSM, TGFB1, IL6, CDH1, LIF
20herbimycin a45 609.8CDH1, ERBB2, MET, IL6, OSM
21methotrexate45 50 1110.8CDH1, BRCA2, BRCA1, TGFB1, IL6, ERBB2
22curcumin458.8CDH1, TGFB1, TP53, ERBB2, IL6
23docetaxel45 50 60 1111.8BRCA2, TGFB1, BRCA1, TP53, ERBB2, CDH1
24etoposide45 50 60 1111.8TGFB1, CDH1, BRCA2, BRCA1, TP53, ERBB2
25doxorubicin45 50 1110.8BRCA1, MET, CDH1, ERBB2, TGFB1, TP53
26p002458.5BRCA1, MET, CDH1, KRT19, BRCA2, ERBB2
27proline458.5TP53, CDH1, BRCA2, BRCA1, IL6ST, MET
28phosphotyrosine458.5OSM, MET, CDH1, IL6ST, ERBB2, BRCA1
29ly294002458.5CDH1, TP53, IL6, ERBB2, TGFB1, VEGFC
30pd 98,059458.4TGFB1, IL6, MET, OSM, CDH1, VEGFC
31ribonucleic acid458.4TGFB1, IL6ST, KRT19, VEGFC, MET, LIF
32agar458.3OSM, BRCA1, MET, LIF, CDH1, IL6ST
33hyaluronic acid45 249.2CDH1, OSM, IL6, KRT19, TGFB1
34oligonucleotide458.2BRCA1, MET, IL6ST, TGFB1, TP53, VEGFC
35steroid458.2OSM, LIF, BRCA1, BRCA2, KRT19, ERBB2
36lactate458.1IL6, LIF, CDH1, TGFB1, ERBB2, KRT19
37dexamethasone45 50 29 1111.1IL6ST, IL6, LIF, OSM, CDH1, TGFB1
38paclitaxel45 50 119.8TP53, LIF, BRCA1, BRCA2, ERBB2, TGFB1
39phosphatidylinositol457.7VEGFC, IL6ST, BRCA1, OSM, MET, ERBB2
40alanine457.7TGFB1, ERBB2, BRCA1, IL6ST, IL6, CDH1
41testosterone45 60 11 2410.7BRCA2, IL6, LIF, VEGFC, CDH1, ERBB2
42genistein45 29 60 2 11 2412.6ERBB2, IL6ST, IL6, CDH1, LIF, MET
43cisplatin45 50 60 1110.5BRCA1, BRCA2, MET, CDH1, KRT19, ERBB2
44serine457.3BRCA1, TGFB1, OSM, LIF, CDH1, IL6ST
45paraffin457.3KRT19, ERBB2, VEGFC, TGFB1, CDH1, TP53
46progesterone45 60 29 11 2411.1BRCA1, BRCA2, MET, LIF, ERBB2, IL6ST
47thymidine45 247.9BRCA1, TGFB1, TP53, KRT19, BRCA2, VEGFC
48tyrosine456.8OSM, MET, VEGFC, LIF, CDH1, IL6
49retinoic acid45 247.0KRT19, TGFB1, TP53, IL6ST, IL6, CDH1
50vegf456.0TGFB1, TP53, KRT19, IL6ST, IL6, CDH1

GO Terms for genes affiliated with Breast Carcinoma in Situ

Sources:
16Gene Ontology
See all sources

Cellular components related to Breast Carcinoma in Situ according to GeneCards/GeneDecks:

idNameGO IDScoreTop Affiliating Genes
1interleukin-6 receptor complexGO:0058969.7IL6ST, IL6
2oncostatin-M receptor complexGO:0059009.4IL6ST, OSM
3focal adhesionGO:0059259.1SDC1, CDH1, BRCA1
4protein complexGO:0432348.8BRCA1, BRCA2, TP53, SDC1
5extracellular regionGO:0055768.1VEGFC, IL6, IL6ST, SDC1, TGFB1, MET
6extracellular spaceGO:0056158.1OSM, LIF, VEGFC, IL6, IL6ST, TGFB1

Biological processes related to Breast Carcinoma in Situ according to GeneCards/GeneDecks:

(show all 32)
idNameGO IDScoreTop Affiliating Genes
1cellular response to indole-3-methanolGO:07168110.2CDH1, BRCA1
2leukemia inhibitory factor signaling pathwayGO:04886110.0LIF, IL6ST
3tyrosine phosphorylation of Stat3 proteinGO:0425039.9LIF, OSM
4positive regulation of astrocyte differentiationGO:0487119.9LIF, IL6ST
5positive regulation of tyrosine phosphorylation of Stat1 proteinGO:0425119.9LIF, IL6ST
6positive regulation of histone deacetylationGO:0310659.9TP53, TGFB1
7negative regulation of neuroblast proliferationGO:0074069.9TP53, TGFB1
8negative regulation of meiosisGO:0458359.9OSM, LIF
9negative regulation of cell-cell adhesionGO:0224089.8TGFB1, CDH1
10positive regulation of histone acetylationGO:0350669.8TGFB1, BRCA1
11interleukin-6-mediated signaling pathwayGO:0701029.8IL6, IL6ST
12DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorGO:0069789.8TP53, BRCA2, BRCA1
13positive regulation of blood vessel endothelial cell migrationGO:0435369.7VEGFC, TGFB1
14double-strand break repairGO:0063029.7BRCA1, BRCA2, TP53
15positive regulation of cell cycle arrestGO:0711589.7BRCA1, TP53, TGFB1
16positive regulation of tyrosine phosphorylation of Stat3 proteinGO:0425179.7IL6ST, IL6, LIF
17negative regulation of hormone secretionGO:0468889.6IL6, LIF, OSM
18positive regulation vascular endothelial growth factor productionGO:0105759.6TGFB1, IL6ST
19positive regulation of cell divisionGO:0517819.6TGFB1, VEGFC, OSM
20positive regulation of MAPK cascadeGO:0434109.5IL6, LIF, OSM
21positive regulation of epithelial cell proliferationGO:0506799.5VEGFC, IL6, ERBB2, TGFB1
22response to X-rayGO:0101659.4TP53, BRCA2
23response to drugGO:0424939.4VEGFC, CDH1, IL6, TGFB1
24positive regulation of acute inflammatory responseGO:0026759.3OSM, IL6, IL6ST
25positive regulation of peptidyl-serine phosphorylationGO:0331389.2TGFB1, IL6, LIF, OSM
26positive regulation of peptidyl-tyrosine phosphorylationGO:0507319.1OSM, LIF, IL6, TP53
27cell proliferationGO:0082838.9OSM, MET, ERBB2, TP53
28negative regulation of cell proliferationGO:0082858.7OSM, LIF, IL6, TP53, TGFB1
29positive regulation of transcription, DNA-dependentGO:0458938.7BRCA1, BRCA2, CDH1, IL6, TP53, TGFB1
30modulation by virus of host morphology or physiologyGO:0190488.4TGFB1, TP53, KRT19, IL6ST
31positive regulation of cell proliferationGO:0082848.4OSM, LIF, VEGFC, IL6, IL6ST, TGFB1
32positive regulation of transcription from RNA polymerase II promoterGO:0459448.2BRCA1, OSM, MET, LIF, IL6, TP53

Molecular functions related to Breast Carcinoma in Situ according to GeneCards/GeneDecks:

idNameGO IDScoreTop Affiliating Genes
1interleukin-6 receptor bindingGO:0051389.5IL6ST, IL6
2protein phosphatase bindingGO:0199039.2MET, CDH1, ERBB2
3growth factor activityGO:0080838.6TGFB1, IL6, VEGFC, LIF, OSM
4protein bindingGO:0055155.9VEGFC, MET, BRCA2, BRCA1, CDH1, IL6ST

Products for genes affiliated with Breast Carcinoma in Situ

  • Antibodies
  • Proteins
  • Lysates
  • Antibodies

Sources for Breast Carcinoma in Situ

3CDC
13ExPASy
14FMA
22GTR
23HGMD
24HMDB
25ICD10
26ICD10 via Orphanet
27ICD9CM
29IUPHAR
30KEGG
35MeSH
36MESH via Orphanet
37MGI
40NCIt
41NDF-RT
44NINDS
45Novoseek
47OMIM
48OMIM via Orphanet
51PubMed
52QIAGEN
58SNOMED-CT via Orphanet
61UMLS
62UMLS via Orphanet